Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

52 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Durability of a sustained virological response, late clinical sequelae, and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C: a prospective study.
Papastergiou V, Stampori M, Lisgos P, Pselas C, Prodromidou K, Karatapanis S. Papastergiou V, et al. Among authors: karatapanis s. Eur J Gastroenterol Hepatol. 2013 Jul;25(7):798-805. doi: 10.1097/MEG.0b013e32835eb8bf. Eur J Gastroenterol Hepatol. 2013. PMID: 23395996
Clinical course of lamivudine monotherapy in patients with decompensated cirrhosis due to HBeAg negative chronic HBV infection.
Manolakopoulos S, Karatapanis S, Elefsiniotis J, Mathou N, Vlachogiannakos J, Iliadou E, Kougioumtzan A, Economou M, Triantos C, Tzourmakliotis D, Avgerinos A. Manolakopoulos S, et al. Among authors: karatapanis s. Am J Gastroenterol. 2004 Jan;99(1):57-63. doi: 10.1046/j.1572-0241.2003.04021.x. Am J Gastroenterol. 2004. PMID: 14687142
Pegylated interferon alfa-2b pen device and ribavirin treatment for patients with chronic hepatitis C: an evaluation of patient satisfaction.
Aggelopoulou-Tiga P, Dimitroulopoulos D, Kaligeros K, Koutsounas S, Kouroumalis E, Diamanti H, Ionnidou P, Kountouras J, Papaioannou C, Dimopoulou M, Giannoulis G, Ketikoglou I, Protopapas A, Bassaris H, Delis V, Karatapanis S, Manolakopoulos S, Mimidis K, Nikolaou A, Thomopoulos K, Tzelas G, Tsianos E, Kardasi M, Perperas A. Aggelopoulou-Tiga P, et al. Among authors: karatapanis s. Eur J Gastroenterol Hepatol. 2010 Sep;22(9):1058-65. doi: 10.1097/meg.0b013e3283399a1b. Eur J Gastroenterol Hepatol. 2010. PMID: 21061492
Evaluation of a four-drug, three-antibiotic, nonbismuth-containing "concomitant" therapy as first-line Helicobacter pylori eradication regimen in Greece.
Georgopoulos S, Papastergiou V, Xirouchakis E, Laudi F, Papantoniou N, Lisgos P, Spiliadi C, Fragou P, Skorda L, Karatapanis S. Georgopoulos S, et al. Among authors: karatapanis s. Helicobacter. 2012 Feb;17(1):49-53. doi: 10.1111/j.1523-5378.2011.00911.x. Helicobacter. 2012. PMID: 22221616 Clinical Trial.
Nonbismuth quadruple "concomitant" therapy versus standard triple therapy, both of the duration of 10 days, for first-line H. pylori eradication: a randomized trial.
Georgopoulos S, Papastergiou V, Xirouchakis E, Laoudi F, Lisgos P, Spiliadi C, Papantoniou N, Karatapanis S. Georgopoulos S, et al. Among authors: karatapanis s. J Clin Gastroenterol. 2013 Mar;47(3):228-32. doi: 10.1097/MCG.0b013e31826015b0. J Clin Gastroenterol. 2013. PMID: 22858517 Clinical Trial.
52 results